A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer

被引:12
|
作者
Zhao, Li [1 ]
Chang, Fei [2 ]
Tong, Yao [2 ]
Yin, Jiawei [2 ]
Xu, Jiawen [3 ]
Li, Hui [1 ]
Du, Lutao [4 ,5 ,6 ]
Jiang, Yanyan [1 ]
机构
[1] Shandong Univ, Sch Mat Sci & Engn, Liquid Solid Struct Evolut & Proc Mat, Minist Educ, Jinan 250061, Shandong, Peoples R China
[2] Shandong Univ, Hosp 2, Jinan 250033, Shandong, Peoples R China
[3] Shandong First Med Univ, Shandong Prov Hosp, Dept Pathol, Jinan 250021, Shandong, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Clin Lab, Jinan 250012, Shandong, Peoples R China
[5] Shandong Prov Key Lab Innovat Technol Lab Med, Jinan 250033, Shandong, Peoples R China
[6] Shandong Prov Clin Med Res Ctr, Clin Lab, Jinan 250033, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
bimetallic AuAg HNSs; chemo-phototherapy; HER2-positive breast cancer; nanotherapeutic platform; pyrotinib;
D O I
10.1002/advs.202308316
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Anti-HER2 (human epidermal growth factor receptor 2) therapies significantly increase the overall survival of patients with HER2-positive breast cancer. Unfortunately, a large fraction of patients may develop primary or acquired resistance. Further, a multidrug combination used to prevent this in the clinic places a significant burden on patients. To address this issue, this work develops a nanotherapeutic platform that incorporates bimetallic gold-silver hollow nanoshells (AuAg HNSs) with exceptional near-infrared (NIR) absorption capability, the small-molecule tyrosine kinase inhibitor pyrotinib (PYR), and Herceptin (HCT). This platform realizes targeted delivery of multiple therapeutic effects, including chemo-and photothermal activities, oxidative stress, and immune response. In vitro assays reveal that the HCT-modified nanoparticles exhibit specific recognition ability and effective internalization by cells. The released PYR inhibit cell proliferation by downregulating HER2 and its associated pathways. NIR laser application induces a photothermal effect and tumor cell apoptosis, whereas an intracellular reactive oxygen species burst amplifies oxidative stress and triggers cancer cell ferroptosis. Importantly, this multimodal therapy also promotes the upregulation of genes related to TNF and NF-kappa B signaling pathways, enhancing immune activation and immunogenic cell death. In vivo studies confirm a significant reduction in tumor volume after treatment, substantiating the potential effectiveness of these nanocarriers. A nanotherapeutic platform targeting HER2-positive breast cancer is developed, consisting of bimetallic gold-silver hollow nanoshells with excellent near-infrared absorption. These nanoshells are loaded with the small-molecule tyrosine kinase inhibitor pyrotinib and surface-modified with Herceptin. This platform realizes targeted delivery of multiple therapeutic effects, including chemo- and photothermal activities, oxidative stress, and immune response. image
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Advances in targeting HER2-positive breast cancer
    Harbeck, Nadia
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2018, 30 (01) : 55 - 59
  • [3] Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
    Holloway, Ryan W.
    Marignani, Paola A.
    CANCERS, 2021, 13 (12)
  • [4] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [5] Targeting HER2-positive breast cancer: advances and future directions
    Swain, Sandra M.
    Shastry, Mythili
    Hamilton, Erika
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (02) : 101 - 126
  • [6] A systematic review of dual targeting in HER2-positive breast cancer
    Kumler, Iben
    Tuxen, Malgorzata K.
    Nielsen, Dorte Lisbet
    CANCER TREATMENT REVIEWS, 2014, 40 (02) : 259 - 270
  • [7] Targeting HER2-positive breast cancer: advances and future directions
    Sandra M. Swain
    Mythili Shastry
    Erika Hamilton
    Nature Reviews Drug Discovery, 2023, 22 : 101 - 126
  • [8] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [9] Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer
    Clavarezza, Matteo
    Venturini, Marco
    ONCOLOGY, 2009, 77 : 14 - 17
  • [10] Targeting SHP2 for the treatment of HER2-positive breast cancer
    Agazie, Y.
    Hartman, Z.
    CANCER RESEARCH, 2019, 79 (04)